THE TREATMENT WITH A COX-2 SPECIFIC INHIBITOR IS EFFECTIVE IN THE MANAGEMENT OF PAIN RELATED TO ENDOMETRIOSIS
| Autor: | Felice Petraglia, Massimo Mazzini, Walter Renato Gioffre, S. Danero, A. Sartini, Luigi Cobellis, Antônio Sérgio Fava, Simona De Simone, Sandro Razzi |
|---|---|
| Přispěvatelé: | Cobellis, Luigi, Razzi, S, DE SIMONE, S, Sartini, A, Fava, A, Danero, S, Gioffre, W, Mazzini, M, Petraglia, F. |
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adult
medicine.medical_specialty Visual analogue scale Reproductive medicine Endometriosis Placebo law.invention Lactones COX-2 specific inhibitor Gynecologic Surgical Procedures Pelvic pain Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans COX-2 specific inhibitors Rofecoxib VAS score Cyclooxygenase Inhibitors Sulfones Endometriosi Pain Postoperative business.industry Obstetrics and Gynecology medicine.disease Surgery Clinical trial Treatment Outcome Reproductive Medicine Female Laparoscopy medicine.symptom business medicine.drug |
| Popis: | Objective: To evaluate the efficacy and safety of a cyclooxygenase (COX)-2 specific inhibitors versus placebo in the treatment of endometriosis-associated pelvic pain. Study design: A group of women (n ¼ 28) with pelvic pain after conservative surgery for symptomatic endometriosis (Stage I and II) were enrolled at the Department of Pediatric, Obstetrics and Reproductive Medicine of University of Siena. A treatment with a COX-2 specific inhibitors (rofecoxib, 25 mg per day) (n ¼ 16) or placebo (n ¼ 12) was given for 6 months. Pelvic pain quantification with a clinical evaluation, including Visual Analogue Scale (VAS) for pain, was performed before and up to 6 months after treatment. Results: A significant improvement of both pelvic pain and dyspareunia was observed after a 6 months persisting since the end of the treatment (P < 0:0001). The efficacy of rofecoxib was higher than placebo and no recurrence occurred, while in the placebo-treatment a 16% (2/12) occurred. No significant side effects have been found with the use of rofecoxib. Conclusions: The use of COX-2 specific inhibitors was effective, safe and low cost therapy in the management of pelvic pain associated to endometriosis and might be also proposed in early stage of endometriosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|